United Imaging Receives Contract from Vizient for its X-ray and Magnetic Resonance Imaging Systems
HOUSTON, March 15, 2022 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has received a contract from Vizient, Inc., for its entire portfolio of DR (X-Ray) and MR (magnetic resonance) systems. The contract expands the number of modalities offered through Vizient by United Imaging, which last year also received a contract for its...
Evercare Group launches Evercare Foundation to help bridge the gap in inequality in healthcare
- The Foundation will provide long-term solutions to improve healthcare access in Africa and South Asia, while contributing to the 2030 Sustainable Development Goals. ISLAMABAD, Pakistan, March 15, 2022 /PRNewswire/ -- The Evercare Group today announced the launch of the Evercare Foundation, a non-profit organization working towards equitable health for all and the development of more resilient health systems across...
I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act
SHANGHAI and GAITHERSBURG, Md., March 15, 2022 /PRNewswire/ -- I-Mab ( "I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provides updates on the recent development relating to the Holding Foreign Companies Accountable Act (the "HFCAA") and its implementation. The...
ROKIT Healthcare’s Latest Paper About Its AI Technology Has Been Accepted to CVPR 2022
SEOUL, South Korea, March 15, 2022 /PRNewswire/ -- ROKIT Healthcare, a global hyper-personalized organ regeneration company, announced on March 7th that its paper about the "AI and 3D bioprinting convergence technology for regenerative treatments" has been accepted to 2022 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR). AI and 3D bioprinting convergence technology...
Business Update on ASC10, an Oral Double Prodrug against COVID-19
HANGZHOU and SHAOXING, China, March 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the business update on its oral double prodrug ASC10 against Coronavirus Disease 2019 (COVID-19): By taking measures below, the manufacturing cost of ASC10 reduced significantly, which is critical to accessibility of COVID-19 drugs. 1. The synthesis process of the key intermediate of ASC10...
Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients
Prospective multicenter study evaluated the safety and efficacy of a PEG-based liquid embolic in treating hypervascular tumors BEDFORD, Mass., March 15, 2022 /PRNewswire/ -- Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of resultsi from the first-in-human clinical trial of Embrace™ Hydrogel Embolic...
Animal health company Emollivet raises capital and strengthens team
GOTHENBURG, Sweden, March 15, 2022 /PRNewswire/ -- Emollivet, the animal health company that develops user-friendly skin care products for animals, is raising capital and recruiting key people. The new share issue, a rights issue to existing owners, amounts to SEK 5 million. On 3rd March, Emollivet launched its first product: Emollivet COMBI - an antiseptic emollient spray for horses with...
Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Lisaftoclax (APG-2575) in R/R CLL/SLL
SUZHOU, China, and ROCKVILLE, Md., Mar. 14, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has dosed the first patient in the pivotal Phase II study of the company's novel Bcl-2 selective inhibitor,...
Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022
SHANGHAI, March 15, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, today announced that it will report financial results for the full year ended December 31, 2021 and provide a business update on March 29, 2022....
European Wellness Biomedical Group and AK International to Bring Biological Regenerative Medicine Solutions to Pakistan and UAE
DUBAI, UAE, March 15, 2022 /PRNewswire/ -- European Wellness Biomedical Group (EWBG) has signed a Memorandum of Agreement (MOA) with Dubai-based AK International LLC (AKI), partnering together to undertake a number of joint venture businesses in Pakistan and the MENA region that focus on providing biological regenerative medicine services and solutions to...
